News Genmab ends lung cancer drug development Genmab has decided to stop development of a drug for cancer, acasunlimab for non-small cell lung cancer, following a review of its pipeline.
Oncology Aligning with national efforts to modernise cancer diagnosti... Andrew Newland, former CEO of ANGLE, explains why live cell liquid biopsies should become standard in oncology.
News Ipsen licenses Simcere ADC in $1bn-plus deal Deal-hungry Ipsen is at it again, pledging around $1bn for rights to an antibody-drug conjugate (ADC) for cancer developed by China's Simcere.
News AZ's ATR inhibitor ceralasertib flunks lung cancer test AstraZeneca has had a setback in its oncology pipeline, as AKT inhibitor ceralasertib fails to improve survival in a phase 3 lung cancer trial.
R&D Q4 Clinical trials round-up: October to December 2025 We round up the key data and innovations in Q4 2025 - and what these likely presage for 2026’s R&D focus.
News J&J's subcutaneous Rybrevant cleared by FDA J&J has claimed FDA approval for Rybrevant Faspro, a subcutaneous version of the lung cancer therapy central to its blockbuster hopes for the drug.
News UK body raps Sanofi for disparaging Pfizer's RSV jab Sanofi been found to be in breach of the UK pharma industry's code of practice over an article in which it compared its RSV jab to a Pfizer rival.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
